We treated with AZA to try to alter the methylation state of 3 cell systems from different GR-positive, GC-resistant human hematological malignancies: acute lymphoblastic leukemias Molt-4 (T-cell), and CEM clone C1-15 (CD4+/CD8+) and the multiple myeloma (B-cell) line RPMI 8226. Here, NR3C1 is linked to hematologic disorder.